Big Pharma, Wide Moats
Innovation and M&A may drive these firms' fortunes.
Pricing pressure is weighing on pharmaceutical and biopharmaceutical companies, but Morningstar’s analysts are optimistic that the major players will continue to support their wide moats, as they explain in a recent Healthcare Observer featuring Morningstar’s annual drug pipeline report. Firms that can develop innovative drugs for critical needs can protect themselves as existing drugs lose patent protection. Meanwhile, this environment is ripe for large-scale consolidation.
I spoke with co-author Damien Conover about opportunities for the industry and investors. Conover, CFA, is director of healthcare equity research with Morningstar Research Services. Our conversation took place on Feb. 19, and valuation data is as of that date. The discussion has been edited for length and clarity.
Laura Lallos has a position in the following securities mentioned above: PFE, SNY. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.